James Xu

Mr. Xu’s recent transactional experience include:

• Aerpio Pharmaceuticals’s listing as a public company through a reverse merger transaction and a concurrent $40 million private placement
• Allena Pharmaceuticals in its $75 million initial public offering
• AquaVenture Holdings in its $117 million initial public offering
• BioAmber in several follow on public offerings raising an aggregate of $120.1 million
• Borderfree in its $80 million initial public offering and subsequent $395 million sale to Pitney Bowes
• Esperion Therapeutics in several follow-on public offerings raising an aggregate of $450 million
• Mimecast in its $77.5 million initial public offering and its $66 million secondary public offering
• Neos Therapeutics in several follow-on public offerings raising an aggregate of $55 million
• ProQR Therapeutics in its $97.5 million initial public offering, several follow-on public offerings raising an aggregate of $26 million and the establishment of its at-the-market facility
• Ra Pharmaceuticals in its $91.6 million initial public offering
• scPharmaceuticals in its $90 million initial public offering
• Vascular Biogenics in its $40 million initial public offering, several follow-on public offerings raising an aggregate of $39 million and the establishment of its at-the-market facility
• Virtusa Corporation in its $91 million follow-on public offering and its $108 million private placement of preferred stock
• The underwriting syndicate in Edge Therapeutics’ $92 million initial public offering
• The underwriting syndicate in InflaRx’s $100 million initial public offering
• The underwriting syndicate in Innocoll AG’s $59 million initial public offering and its subsequent follow-on public offering raising an aggregate of $70 million
• The underwriting syndicate in Nivalis Therapeutics’ $88 million initial public offering
• The underwriting syndicate in Paylocity’s $138 million initial public offering
• The underwriting syndicate in Tokai Pharmaceuticals’ $97 million initial public offering